.png)
Many stocks will benefit from the rollout of the Covid 19 vaccine.
According to a Bank of America research note, “Companies in bioprocess and manufacturing may see revenues if a vaccine is produced at risk and never approved, while others, like drugstores, benefit only if people are vaccinated,” the team wrote. “Logistics companies tend to be somewhere in the middle, benefiting from some at-risk production but ultimately, the vaccine needs to be consumed and re-ordered for real benefits to accrue.”
Of the names they mention, I’ve filtered down to the ones which meet my tighter filters of cash flow growth, earnings growth, and a share price which is not high relative to profits the company makes.
Stocks of Covid 19: Danaher
Market cap: $158.97 billion
Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)
Vaccine supply chain category: Manufacturing
Source: Bank of America
Stocks of Covidm 19: Thermo Fisher
Market cap: $186.86 billion
Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)
Vaccine supply chain category: Manufacturing
Source: Bank of America
Stocks of Covid 19: Merck
Market cap: $209.93 billion
Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)
Vaccine supply chain category: Manufacturing
Source: Bank of America
Source: Bank of America, Business Insider
Alpesh Patel